Drug intelligence / Profile preview

bocitinib

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Bocitinib is described in some scientific contexts as a small molecule Janus kinase (JAK) inhibitor, similar in class to baricitinib and tofacitinib. Its mechanism of action is presumed to involve inhibition of JAK enzymes, particularly affecting JAK1 and JAK2, which play key roles in signaling pathways mediating inflammation and immune regulation. The drug has been mentioned in some early-stage research as a potential treatment for autoimmune diseases, especially rheumatoid arthritis, due to its immunomodulatory actions. Precise details regarding its developer, approved indications, and clinical development remain limited and are not widely established in authoritative medical or regulatory sources.

Brand names: bocitinib
Other names: bocitinib

Targets

TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on bocitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bocitinib.

Explore the full profile